What is Fosanis?
Founded in 2017 by Dr. Gandolf Finke and Dr. Jan Simon Raue, Fosanis GmbH is a digital health company dedicated to enhancing the lives of individuals affected by cancer through innovative digital solutions. The company has developed Mika, an AI-powered digital therapeutic (DTx) platform, in collaboration with leading oncological research institutions and cancer centers, including the University of Leipzig Medical Center and Charité Berlin. Mika achieved a significant milestone in 2021 by becoming the first and only 'digital health application' (DiGA) approved for all cancer patients. This personalized platform integrates AI-driven monitoring and coaching, utilizing scientifically validated methods and therapy management techniques to support patients throughout their disease and treatment journey. Daily electronic patient-reported outcomes (ePROs) enable continuous tracking of distress levels and symptoms, complemented by a personalized coaching program offering scientifically validated multimedia elements and psycho-oncological interventions.
How much funding has Fosanis raised?
Fosanis has raised a total of $10.6M across 1 funding round:
Series A
$10.6M
Series A (2022): $10.6M with participation from Ananda Ventures, Ship2B Ventures, and EquityPitcher
Key Investors in Fosanis
Ananda Ventures
Ananda Ventures is a venture capital firm focused on investing in innovative technologies that address critical challenges in healthcare and sustainability, aiming to improve health and quality of life.
Ship2B Ventures
Ship2B Ventures invests in impact startups addressing social and environmental challenges, supporting early-stage companies with a focus on systemic change and disruptive innovation.
EquityPitcher
EquityPitcher Ventures backs world-changing technologies and innovative entrepreneurs, leveraging an extensive industry network to support B2B tech startups with impactful solutions.
What's next for Fosanis?
The recent major strategic investment in Fosanis signals a strong validation of its innovative approach to oncology care. This capital infusion is expected to fuel further development and expansion of the Mika platform, potentially enhancing its AI capabilities, broadening its therapeutic applications, and increasing its reach to a wider patient population. The company's focus on digital therapeutics and its established partnerships with research institutions position it for continued growth and impact in the evolving landscape of digital health and cancer treatment.
See full Fosanis company page
